Trial Profile

Phase I study of ARM 210 (S48168) for the treatment of Duchenne muscular dystrophy

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 10 Dec 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Surlorian (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions
Sponsors RyCarma Therapeutics; Servier

Most Recent Events

10 Dec 2014 New trial record
04 Dec 2014 This trial is expected to begin in 2015 after receipt of input from regulatory agencies, according to a media release from ARMGO Pharma and Servier.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com